ACT IV, a phase III trial evaluating Rindopepimut (also known as CDX-110), a 13-amino acid peptide vaccine targeting EGFRvIII, a constitutively active mutant form of EGFR expressed in ~30% of GBM patients, in combination with TMZ was terminated for futility, as no significant difference in mOS was observed in patients with newly-diagnosed GBM (73). Here, EGFR is linked to glioblastoma.